ONCOBONE VENTURES AND ORIGENIS ANNOUNCE PARTNERSHIP TO DEVELOP NOVEL THERAPIES FOR CANCER BONE METASTASIS

London, UK – OncoBone Ventures Ltd, based in the UK, and Origenis GmbH, headquartered in Planegg, Germany, have signed a Framework Agreement to develop novel therapies targeting cancer bone metastasis, addressing a significant unmet medical need. Currently, there are no effective treatments for bone metastases, which affect 70-90% of advanced breast and prostate cancer patients, with less than 5% surviving beyond five years post-diagnosis.

Press release Origenis OncoBone.pdf

PDF herunterladen • 104KB